U.S. Markets close in 2 hrs 11 mins

Why Has Valeant Stock Fallen in June?

Kenneth Smith
Why Has Valeant Stock Fallen in June?

Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.